Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-platelet aggregation polypeptide and application thereof

An anti-platelet aggregation and platelet aggregation technology, which is applied in the field of medicine and biology, can solve the problems of increasing the risk of cerebral hemorrhage in patients and the lack of activity of polypeptide 15012, etc., and achieve the effect of inhibiting platelet aggregation, inhibiting platelet aggregation, and convenient use

Active Publication Date: 2021-09-24
FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical trials have shown that while vorapaxar inhibits platelet aggregation, it also increases the risk of cerebral hemorrhage in patients
[0005] At present, there is no report on the anti-platelet aggregation polypeptide 15012 and its activity in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-platelet aggregation polypeptide and application thereof
  • Anti-platelet aggregation polypeptide and application thereof
  • Anti-platelet aggregation polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] According to the method reported in the literature (La Face DM, Couture C, Anderson K, et al. Differential T cell signaling induced by antagonist peptide-MHC complexes and the associated phenotypic responses. J Immunol. 1997 Mar 1; 158(5): 2057–2064.) , the peptide 15012 was synthesized using the method of solid-phase peptide synthesis. The synthesized polypeptide was purified by high performance liquid chromatography (HPLC), and the concentration reached ≥95% (attached figure 1 ). Subsequently, the amino acid sequence and molecular weight were determined by mass spectrometry (MS), and the clearly synthesized polypeptide was 15012 (attached figure 2 ).

[0033] Peptide 15012 inhibits thrombin-induced human platelet aggregation in vitro.

[0034] (1) Source of experimental human platelets Healthy volunteers signed informed consent for blood donation and were given certain nutritional subsidies. Venous whole blood was collected, apheresis platelets were separated by ...

specific Embodiment approach

[0036] Step 1, dissolve with DMSO and adjust the concentration of 15012 to 400mM and 200mM.

[0037] Step 2, washing the platelets. Take 1mL human apheresis platelets stored at 25°C with constant temperature and shaking in a 1.5mL centrifuge tube, add EDTA at a final concentration of 5mM and 0.1U / mL Apyrase (prepared with normal saline to prevent platelet aggregation during centrifugation), and centrifuge at room temperature at 400g 10 minutes; discard the supernatant of the centrifuged human apheresis platelets, add 1mL Tyrode's Buffer B (137mM NaCl, 27mM KCl, 1mM MgCl 2 , 0.42mM NaH 2 PO 4 , 5.5mM Glucose, 5.55mM HEPES, 0.25% Bovine Serum Albumin, pH 6.5), 5mM EDTA, 0.1U / mL Apyrase, blow gently, centrifuge again at 400g room temperature for 10 minutes; MgCl 2 ,0.42mM NaH 2 PO 4 , 5.5mM Glucose, 5.55mM HEPES, 0.25% Bovine Serum Albumin, pH 7.4) resuspend the centrifuged platelets, and adjust the platelet count to 150-250×10 9 / L. Store with shaking at 70 rpm at 25°C, ...

Embodiment 2

[0041] Peptide 15012 inhibits platelet clot retraction.

[0042] (1) The source of experimental human platelets is the same as in Example 1.

[0043] (2) The specific implementation method is as follows:

[0044] Platelet-rich plasma was diluted with Tyrode's Buffer A and quantified to 500×10 9 / L, put 200 μL of platelet-rich plasma into a siliconized transparent glass tube, and incubate at 37°C for 20 minutes. Dissolve 15012 in DMSO and adjust the concentration to 400mM. The experimental groups were: positive control group (Thrombin 0.2U / mL), negative control group (Control) and 15012 experimental group. Add 15012 with a final concentration of 4mM to the experimental group, add DMSO equal to the volume of the experimental group to the positive control group and negative control group, and incubate at 37°C for 20 minutes. After incubation, add thrombin at a final concentration of 0.2 U / mL to the positive control group and 15012 experimental tubes, mix well, and then stand ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a polypeptide 15012 for resisting platelet aggregation, and belongs to the technical field of medical biology. The polypeptide disclosed by the invention is composed of 10 amino acids, has a sequence of the polypeptide as shown in SEQ ID NO: 1, has a molecular weight of 1033.05, and has a sequence of Asp-Thr-Pro-Thr-Ile-Ser-Pro-Ser-Asp-Thr. The polypeptide is not limited to inhibition of thrombin-induced platelet aggregation, can be used for exploring the influence of the polypeptide and other platelet activators (collagen, arachidonic acid, ADP, epinephrine, ristomycin and the like) on the action and related functions of platelets, and can also be used for monitoring existing antiplatelet treatment.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and relates to a polypeptide, in particular to an anti-platelet aggregation polypeptide 15012, a preparation method thereof, a pharmaceutical composition composed of it as an active ingredient, and its use in the preparation of anti-platelet drugs Applications. [0002] technical background [0003] The incidence, mortality, disability and recurrence rate of thrombotic events in cardiovascular and cerebrovascular diseases have been increasing year by year, which not only brings a heavy economic burden to patients, but also causes certain damage to their physiology and psychology, resulting in a decline in the quality of life of patients . Activation of platelets is central to thrombus formation, so antiplatelet therapy is important in the management of cardiovascular disease. At present, clinical antiplatelet drugs still have bleeding risks, individual differences in efficacy, and drug resis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K38/08A61P7/02
CPCC07K7/06A61P7/02A61K38/00
Inventor 孟照辉叶雨佳金天颖杨晓娜李井美董玲
Owner FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com